We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y
Read MoreHide Full Article
Key Takeaways
MTD posted Q4 adjusted EPS of $13.36, beating estimates, while net sales climbed 8% year over year to $1.13B.
Laboratory, Industrial and Food Retail delivered LC growth of 3%, 7% and 19%, driving the quarter's top line.
Mettler-Toledo guided for Q1 2026 sales up about 3% locally and adjusted EPS of $8.60-$8.75.
Mettler-Toledo International (MTD - Free Report) reported fourth-quarter 2025 adjusted earnings of $13.36 per share, which beat the Zacks Consensus Estimate by 4.67%. The bottom line increased 8% on a year-over-year basis.
Net sales of $1.13 billion surpassed the Zacks Consensus Estimate by 2.53%. The figure increased 8% on a reported basis and 5% on a local currency basis from the year-ago quarter.
MTD’s Q4 Top Line in Detail
MTD reported revenues under three segments, namely Laboratory, Industrial and Food Retail, which generated sales of $638 million (56.5% of the net sales), $437 million (38.7% of the net sales) and $54 million (4.8% of the net sales), respectively, in the fourth quarter. The Laboratory, Industrial, and Food Retail segments witnessed year-over-year growth of 3%, 7% and 19%, respectively, on a local currency basis.
Total sales from the Americas, Europe and Asia/Rest of the World were $456 million (40.4% of the net sales), $346 million (30.6%) and $328 million (29.1%), respectively. Sales in the Americas, Europe and Asia / Rest of the World increased 7%, 4% and 4% year over year, respectively, on a local currency basis.
Mettler-Toledo International, Inc. Price, Consensus and EPS Surprise
In the fourth quarter of 2025, the gross margin was 59.8%, which contracted 140 basis points (bps) year over year.
Research & development (R&D) expenses were $52.6 million, up 5.1% year over year. Selling, general & administrative (SG&A) expenses increased 9.5% year over year to $259.8 million. As a percentage of sales, R&D expenses decreased 10 bps year over year. SG&A expenses increased 30 bps year over year as a percentage of sales.
The adjusted operating margin was 32.2%, which declined 150 bps year over year.
MTD’s Balance Sheet & Cash Flow
As of Dec. 31, 2025, Mettler-Toledo’s cash and cash-equivalent balance was $66.9 million, down from $69.1 million as of Sept. 30. The long-term debt was $2.09 billion as of Sept. 30, 2025.
Mettler-Toledo generated $225.6 million in cash from operating activities in the reported quarter. The free cash flow was $188.1 million in the reported quarter.
Mettler-Toledo’s Q1 and FY26 Guidance
For the first quarter of 2026, Mettler-Toledo anticipates sales to increase roughly 3% in local currency year over year.
Adjusted earnings are anticipated to be between $8.60 per share and $8.75 per share, a growth rate of 5% to 7% year over year.
For 2026, Mettler-Toledo anticipates sales in local currency to increase approximately 4% over 2024. The company expects adjusted earnings between $46.05 per share and $46.70 per share, representing 8-9% growth over 2025.
Zacks Rank & Stocks to Consider
Currently, Mettler-Toledo carries a Zacks Rank #3 (Hold).
Actuate Therapeutics (ACTU - Free Report) , Alkermes (ALKS - Free Report) and Amneal Pharmaceuticals (AMRX - Free Report) are some better-ranked stocks that investors can consider in the broader Zacks Medical sector.
Actuate Therapeutics shares have dropped 49.2% in the trailing 12-month period. The company is scheduled to release fourth-quarter 2025 results on Mar. 12. ACTU carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Alkermes shares have returned 9.8% in the trailing 12-month period. ALKS is scheduled to release fourth-quarter 2025 results on Feb. 11. Alkermes sports a Zacks Rank #1.
Amneal Pharmaceuticals has returned 87.1% in the trailing 12-month period. AMRX is set to report its fourth-quarter 2025 results on Feb. 27. The company currently carries a Zacks Rank #2.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y
Key Takeaways
Mettler-Toledo International (MTD - Free Report) reported fourth-quarter 2025 adjusted earnings of $13.36 per share, which beat the Zacks Consensus Estimate by 4.67%. The bottom line increased 8% on a year-over-year basis.
Net sales of $1.13 billion surpassed the Zacks Consensus Estimate by 2.53%. The figure increased 8% on a reported basis and 5% on a local currency basis from the year-ago quarter.
MTD’s Q4 Top Line in Detail
MTD reported revenues under three segments, namely Laboratory, Industrial and Food Retail, which generated sales of $638 million (56.5% of the net sales), $437 million (38.7% of the net sales) and $54 million (4.8% of the net sales), respectively, in the fourth quarter. The Laboratory, Industrial, and Food Retail segments witnessed year-over-year growth of 3%, 7% and 19%, respectively, on a local currency basis.
Total sales from the Americas, Europe and Asia/Rest of the World were $456 million (40.4% of the net sales), $346 million (30.6%) and $328 million (29.1%), respectively. Sales in the Americas, Europe and Asia / Rest of the World increased 7%, 4% and 4% year over year, respectively, on a local currency basis.
Mettler-Toledo International, Inc. Price, Consensus and EPS Surprise
Mettler-Toledo International, Inc. price-consensus-eps-surprise-chart | Mettler-Tole Mettler-Toledo’s Q4 Operating Details
Mettler-Toledo’s Q4 Operating Details
In the fourth quarter of 2025, the gross margin was 59.8%, which contracted 140 basis points (bps) year over year.
Research & development (R&D) expenses were $52.6 million, up 5.1% year over year. Selling, general & administrative (SG&A) expenses increased 9.5% year over year to $259.8 million. As a percentage of sales, R&D expenses decreased 10 bps year over year. SG&A expenses increased 30 bps year over year as a percentage of sales.
The adjusted operating margin was 32.2%, which declined 150 bps year over year.
MTD’s Balance Sheet & Cash Flow
As of Dec. 31, 2025, Mettler-Toledo’s cash and cash-equivalent balance was $66.9 million, down from $69.1 million as of Sept. 30. The long-term debt was $2.09 billion as of Sept. 30, 2025.
Mettler-Toledo generated $225.6 million in cash from operating activities in the reported quarter. The free cash flow was $188.1 million in the reported quarter.
Mettler-Toledo’s Q1 and FY26 Guidance
For the first quarter of 2026, Mettler-Toledo anticipates sales to increase roughly 3% in local currency year over year.
Adjusted earnings are anticipated to be between $8.60 per share and $8.75 per share, a growth rate of 5% to 7% year over year.
For 2026, Mettler-Toledo anticipates sales in local currency to increase approximately 4% over 2024. The company expects adjusted earnings between $46.05 per share and $46.70 per share, representing 8-9% growth over 2025.
Zacks Rank & Stocks to Consider
Currently, Mettler-Toledo carries a Zacks Rank #3 (Hold).
Actuate Therapeutics (ACTU - Free Report) , Alkermes (ALKS - Free Report) and Amneal Pharmaceuticals (AMRX - Free Report) are some better-ranked stocks that investors can consider in the broader Zacks Medical sector.
Actuate Therapeutics shares have dropped 49.2% in the trailing 12-month period. The company is scheduled to release fourth-quarter 2025 results on Mar. 12. ACTU carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Alkermes shares have returned 9.8% in the trailing 12-month period. ALKS is scheduled to release fourth-quarter 2025 results on Feb. 11. Alkermes sports a Zacks Rank #1.
Amneal Pharmaceuticals has returned 87.1% in the trailing 12-month period. AMRX is set to report its fourth-quarter 2025 results on Feb. 27. The company currently carries a Zacks Rank #2.